Compare ADMA Biologics Inc (ADMA) vs Hasbro, Inc. (HAS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Hasbro, Inc. — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while Hasbro, Inc. trades at $75.78 (market cap $10.86B). The key difference: Hasbro, Inc. is far larger — about 5.1× ADMA Biologics Inc's market cap, and Hasbro, Inc. pays a 3.65% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | HAS | |
|---|---|---|
Market Cap | $2.13B | $10.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $105.88 |
52-Week Low | $7.60 | $70.95 |
Enterprise Value | $2.20B | $13.12B |
Dividend Yield | — | 3.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Hasbro (HAS) trades at $76.73, down 4.27% on the day, with a bearish technical signal but oversold RSI readings suggesting potential reversal. The company reported a net loss of $322.4 million in 2025 despite revenue growth to $4.70 billion, with strong earnings beats in recent quarters. Analyst consensus is bullish with a $107.40 price target, while institutional sentiment remains mixed amid high debt levels and profitability challenges.
The outlook hinges on earnings execution and debt management, with upside from Wizards segment growth and digital initiatives. Key risks include sustained negative margins, $3.38 billion long-term debt burden, and consumer discretionary volatility. Near-term catalyst is Q2 2026 earnings on July 21, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →
